-
1
-
-
0019974098
-
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
-
Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10(2):201-227.
-
(1982)
J Pharmacokinet Biopharm
, vol.10
, Issue.2
, pp. 201-227
-
-
Boxenbaum, H.1
-
2
-
-
0032921527
-
Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations
-
Lave T, Coassolo P, Reigner B. 1999. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36(3):211-231.
-
(1999)
Clin Pharmacokinet
, vol.36
, Issue.3
, pp. 211-231
-
-
Lave, T.1
Coassolo, P.2
Reigner, B.3
-
3
-
-
0026063359
-
Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins
-
Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8(11):1351-1359.
-
(1991)
Pharm Res
, vol.8
, Issue.11
, pp. 1351-1359
-
-
Mordenti, J.1
Chen, S.A.2
Moore, J.A.3
Ferraiolo, B.L.4
Green, J.D.5
-
4
-
-
0347755132
-
Interspecies scaling of protein drugs: Prediction of clearance from animals to humans
-
Mahmood I. 2004. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 93(1):177-185.
-
(2004)
J Pharm Sci
, vol.93
, Issue.1
, pp. 177-185
-
-
Mahmood, I.1
-
5
-
-
77955297665
-
Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited
-
Wang W, Prueksaritanont T. 2010. Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Biopharm Drug Dispos 31(4):253-263.
-
(2010)
Biopharm Drug Dispos
, vol.31
, Issue.4
, pp. 253-263
-
-
Wang, W.1
Prueksaritanont, T.2
-
6
-
-
78751499845
-
Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction
-
Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. 2011. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmcokinet 50(2):131-142.
-
(2011)
Clin Pharmcokinet
, vol.50
, Issue.2
, pp. 131-142
-
-
Dong, J.Q.1
Salinger, D.H.2
Endres, C.J.3
Gibbs, J.P.4
Hsu, C.P.5
Stouch, B.J.6
Hurh, E.7
Gibbs, M.A.8
-
7
-
-
84868210960
-
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs
-
Agerso H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M. 2012. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 18(6):941-947.
-
(2012)
Haemophilia
, vol.18
, Issue.6
, pp. 941-947
-
-
Agerso, H.1
Stennicke, H.R.2
Pelzer, H.3
Olsen, E.N.4
Merricks, E.P.5
Defriess, N.A.6
Nichols, T.C.7
Ezban, M.8
-
8
-
-
77955492929
-
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
-
Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE. 2010. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 116(2):270-279.
-
(2010)
Blood
, vol.116
, Issue.2
, pp. 270-279
-
-
Mei, B.1
Pan, C.2
Jiang, H.3
Tjandra, H.4
Strauss, J.5
Chen, Y.6
Liu, T.7
Zhang, X.8
Severs, J.9
Newgren, J.10
Chen, J.11
Gu, J.M.12
Subramanyam, B.13
Fournel, M.A.14
Pierce, G.F.15
Murphy, J.E.16
-
9
-
-
84873625664
-
BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation
-
Turecek PL, Bossard MJ, Graninger M, Gritsch H, Hollriegl W, Kaliwoda M, Matthiessen P, Mitterer A, Muchitsch EM, Purtscher M, Rottensteiner H, Schiviz A, Schrenk G, Siekmann J, Varadi K, Riley T, Ehrlich HJ, Schwarz HP, Scheiflinger F. 2012. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 32 Suppl 1:S29-S38.
-
(2012)
Hamostaseologie
, vol.32
, Issue.SUPPL 1
-
-
Turecek, P.L.1
Bossard, M.J.2
Graninger, M.3
Gritsch, H.4
Hollriegl, W.5
Kaliwoda, M.6
Matthiessen, P.7
Mitterer, A.8
Muchitsch, E.M.9
Purtscher, M.10
Rottensteiner, H.11
Schiviz, A.12
Schrenk, G.13
Siekmann, J.14
Varadi, K.15
Riley, T.16
Ehrlich, H.J.17
Schwarz, H.P.18
Scheiflinger, F.19
-
10
-
-
20444503381
-
Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy
-
Baru M, Carmel-Goren L, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J. 2005. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 93(6):1061-1068.
-
(2005)
Thromb Haemost
, vol.93
, Issue.6
, pp. 1061-1068
-
-
Baru, M.1
Carmel-Goren, L.2
Barenholz, Y.3
Dayan, I.4
Ostropolets, S.5
Slepoy, I.6
Gvirtzer, N.7
Fukson, V.8
Spira, J.9
-
11
-
-
77955962214
-
Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice
-
Peng A, Straubinger RM, Balu-Iyer SV. 2010. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 12(3):473-481.
-
(2010)
AAPS J
, vol.12
, Issue.3
, pp. 473-481
-
-
Peng, A.1
Straubinger, R.M.2
Balu-Iyer, S.V.3
-
12
-
-
59849090731
-
Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations
-
Wakabayashi H, Griffiths AE, Fay PJ. 2009. Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations. J Thromb Haemost 7(3):438-444.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.3
, pp. 438-444
-
-
Wakabayashi, H.1
Griffiths, A.E.2
Fay, P.J.3
-
13
-
-
0030664471
-
Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
-
Pipe SW, Kaufman RJ. 1997. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 94(22):11851-11856.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, Issue.22
, pp. 11851-11856
-
-
Pipe, S.W.1
Kaufman, R.J.2
-
14
-
-
84859197329
-
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
-
Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. 2012. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 119(13):3031-3037.
-
(2012)
Blood
, vol.119
, Issue.13
, pp. 3031-3037
-
-
Powell, J.S.1
Josephson, N.C.2
Quon, D.3
Ragni, M.V.4
Cheng, G.5
Li, E.6
Jiang, H.7
Li, L.8
Dumont, J.A.9
Goyal, J.10
Zhang, X.11
Sommer, J.12
McCue, J.13
Barbetti, M.14
Luk, A.15
Pierce, G.F.16
-
15
-
-
84859192874
-
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
-
Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HW, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H. 2012. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 119(13):3024-3030.
-
(2012)
Blood
, vol.119
, Issue.13
, pp. 3024-3030
-
-
Dumont, J.A.1
Liu, T.2
Low, S.C.3
Zhang, X.4
Kamphaus, G.5
Sakorafas, P.6
Fraley, C.7
Drager, D.8
Reidy, T.9
McCue, J.10
Franck, H.W.11
Merricks, E.P.12
Nichols, T.C.13
Bitonti, A.J.14
Pierce, G.F.15
Jiang, H.16
-
16
-
-
0030040359
-
Pharmacokinetics and interspecies scaling of recombinant human factor VIII
-
Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. 1996. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 136(1):75-78.
-
(1996)
Toxicol Appl Pharmacol
, vol.136
, Issue.1
, pp. 75-78
-
-
Mordenti, J.1
Osaka, G.2
Garcia, K.3
Thomsen, K.4
Licko, V.5
Meng, G.6
-
17
-
-
69949089085
-
Pharmacokinetic allometric scaling of coagulation factors and tissue-type plasminogen activators
-
Mahmood I. 2009. Pharmacokinetic allometric scaling of coagulation factors and tissue-type plasminogen activators. Haemophilia 15(5):1109-1117.
-
(2009)
Haemophilia
, vol.15
, Issue.5
, pp. 1109-1117
-
-
Mahmood, I.1
-
18
-
-
3042648079
-
Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles
-
Wajima T, Yano Y, Fukumura K, Oguma T. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93(7):1890-1900.
-
(2004)
J Pharm Sci
, vol.93
, Issue.7
, pp. 1890-1900
-
-
Wajima, T.1
Yano, Y.2
Fukumura, K.3
Oguma, T.4
-
19
-
-
0023028352
-
NONLIN84/PCNONLIN: Software for the statistical analysis of nonlinear models
-
Weiner DL. 1986. NONLIN84/PCNONLIN: Software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol 8(10):625-628.
-
(1986)
Methods Find Exp Clin Pharmacol
, vol.8
, Issue.10
, pp. 625-628
-
-
Weiner, D.L.1
-
20
-
-
70349555987
-
2000 CDC Growth Charts for the United States: methods and development. Vital and health statistics Series 11
-
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL 2002. 2000 CDC Growth Charts for the United States: methods and development. Vital and health statistics Series 11, Data from the national health survey (246):1-190.
-
(2002)
Data from the national health survey
, Issue.246
, pp. 1-190
-
-
Kuczmarski, R.J.1
Ogden, C.L.2
Guo, S.S.3
Grummer-Strawn, L.M.4
Flegal, K.M.5
Mei, Z.6
Wei, R.7
Curtin, L.R.8
Roche, A.F.9
Johnson, C.L.10
-
21
-
-
84855853759
-
Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight
-
Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. 2012. Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight. Blood 119(2):612-618.
-
(2012)
Blood
, vol.119
, Issue.2
, pp. 612-618
-
-
Bjorkman, S.1
Oh, M.2
Spotts, G.3
Schroth, P.4
Fritsch, S.5
Ewenstein, B.M.6
Casey, K.7
Fischer, K.8
Blanchette, V.S.9
Collins, P.W.10
-
22
-
-
70349229281
-
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A
-
Bjorkman S, Folkesson A, Jonsson S. 2009. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: A population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 65(10):989-998.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, Issue.10
, pp. 989-998
-
-
Bjorkman, S.1
Folkesson, A.2
Jonsson, S.3
-
23
-
-
84859192874
-
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
-
Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HW, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H. 2012. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 119:3024-3030.
-
(2012)
Blood
, vol.119
, pp. 3024-3030
-
-
Dumont, J.A.1
Liu, T.2
Low, S.C.3
Zhang, X.4
Kamphaus, G.5
Sakorafas, P.6
Fraley, C.7
Drager, D.8
Reidy, T.9
McCue, J.10
Franck, H.W.11
Merricks, E.P.12
Nichols, T.C.13
Bitonti, A.J.14
Pierce, G.F.15
Jiang, H.16
-
24
-
-
84859197329
-
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
-
Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. 2012. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 119:3031-3037.
-
(2012)
Blood
, vol.119
, pp. 3031-3037
-
-
Powell, J.S.1
Josephson, N.C.2
Quon, D.3
Ragni, M.V.4
Cheng, G.5
Li, E.6
Jiang, H.7
Li, L.8
Dumont, J.A.9
Goyal, J.10
Zhang, X.11
Sommer, J.12
McCue, J.13
Barbetti, M.14
Luk, A.15
Pierce, G.F.16
-
25
-
-
0021970348
-
Kinetic evaluation of four Factor VIII concentrates by model-independent methods
-
Matucci M, Messori A, Donati-Cori G, Longo G, Vannini S, Morfini M, Tendi E, Rossi-Ferrini PL. 1985. Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand J Haematol 34(1):22-28.
-
(1985)
Scand J Haematol
, vol.34
, Issue.1
, pp. 22-28
-
-
Matucci, M.1
Messori, A.2
Donati-Cori, G.3
Longo, G.4
Vannini, S.5
Morfini, M.6
Tendi, E.7
Rossi-Ferrini, P.L.8
-
26
-
-
0024273204
-
Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs
-
Messori A, Longo G, Morfini M, Cinotti S, Filimberti E, Giustarini G, Rossi Ferrini P. 1988. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 35(6):663-668.
-
(1988)
Eur J Clin Pharmacol
, vol.35
, Issue.6
, pp. 663-668
-
-
Messori, A.1
Longo, G.2
Morfini, M.3
Cinotti, S.4
Filimberti, E.5
Giustarini, G.6
Rossi, F.P.7
-
27
-
-
0024412249
-
The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma
-
Rousell RH, Kasper CK, Schwartz RS. 1989. The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma. Transfusion 29(3):208-212.
-
(1989)
Transfusion
, vol.29
, Issue.3
, pp. 208-212
-
-
Rousell, R.H.1
Kasper, C.K.2
Schwartz, R.S.3
-
28
-
-
0025644310
-
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
-
the Recomb ant Factor VIII Study Group.
-
Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, Kasper CK, Kernoff PBA, Levine PH, Lusher JM, Mannucci PM, Scharrer IS, MacKenzie MA, Pancham N, Kuo HS, Allred RU, and the Recombinant Factor VIII Study Group. 1990. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 323(26):1800-1805.
-
(1990)
N Engl J Med
, vol.323
, Issue.26
, pp. 1800-1805
-
-
Schwartz, R.S.1
Abildgaard, C.F.2
Aledort, L.M.3
Arkin, S.4
Bloom, A.L.5
Brackmann, H.H.6
Brettler, D.B.7
Fukui, H.8
Hilgartner, M.W.9
Inwood, M.J.10
Kasper, C.K.11
Kernoff, P.B.A.12
Levine, P.H.13
Lusher, J.M.14
Mannucci, P.M.15
Scharrer, I.S.16
MacKenzie, M.A.17
Pancham, N.18
Kuo, H.S.19
Allred, R.U.20
more..
-
29
-
-
0025164545
-
Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC
-
Smith KJ, Lusher JM, Cohen AR, Salzman P. 1990. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol 27(2 Suppl 2):25-29.
-
(1990)
Semin Hematol
, vol.27
, Issue.2 SUPPL 2
, pp. 25-29
-
-
Smith, K.J.1
Lusher, J.M.2
Cohen, A.R.3
Salzman, P.4
-
30
-
-
0025755874
-
The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial Group
-
discussion 36.
-
Harrison JF, Bloom AL, Abildgaard CF. 1991. The pharmacokinetics of recombinant factor VIII. The rFactor VIII Clinical Trial Group. Semin Hematol 28(2 Suppl 1 ):29-35; discussion 36.
-
(1991)
Semin Hematol
, vol.28
, Issue.2 SUPPL 1
, pp. 29-35
-
-
Harrison, J.F.1
Bloom, A.L.2
Abildgaard, C.F.3
-
31
-
-
0025954632
-
In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates
-
Kasper CK, Kim HC, Gomperts ED, Smith KJ, Salzman PM, Tipping D, Miller R, Montgomery RM. 1991. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates. Thromb Haemost 66(6):730-733.
-
(1991)
Thromb Haemost
, vol.66
, Issue.6
, pp. 730-733
-
-
Kasper, C.K.1
Kim, H.C.2
Gomperts, E.D.3
Smith, K.J.4
Salzman, P.M.5
Tipping, D.6
Miller, R.7
Montgomery, R.M.8
-
32
-
-
0025822381
-
Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates
-
Morfini M, Mannucci PM, Longo G, Cinotti S, Messori A. 1991. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. Thromb Res 61(3):285-290.
-
(1991)
Thromb Res
, vol.61
, Issue.3
, pp. 285-290
-
-
Morfini, M.1
Mannucci, P.M.2
Longo, G.3
Cinotti, S.4
Messori, A.5
-
33
-
-
0026609355
-
Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies
-
Bjorkman S, Carlsson M, Berntorp E, Stenberg P. 1992. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 22(5):385-395.
-
(1992)
Clin Pharmacokinet
, vol.22
, Issue.5
, pp. 385-395
-
-
Bjorkman, S.1
Carlsson, M.2
Berntorp, E.3
Stenberg, P.4
-
34
-
-
0026736639
-
Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity
-
Messori A, Morfini M, Blomback M, Cinotti S, Longo G, Schimpf K, Schumacher K, Novakova-Banet A, Delvos U, Kjellman H. 1992. Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity. Thromb Res 65(6):699-708.
-
(1992)
Thromb Res
, vol.65
, Issue.6
, pp. 699-708
-
-
Messori, A.1
Morfini, M.2
Blomback, M.3
Cinotti, S.4
Longo, G.5
Schimpf, K.6
Schumacher, K.7
Novakova-Banet, A.8
Delvos, U.9
Kjellman, H.10
-
35
-
-
0026706388
-
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group
-
Morfini M, Longo G, Messori A, Lee M, White G, Mannucci P. 1992. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group. Thromb Haemost 68(4):433-435.
-
(1992)
Thromb Haemost
, vol.68
, Issue.4
, pp. 433-435
-
-
Morfini, M.1
Longo, G.2
Messori, A.3
Lee, M.4
White, G.5
Mannucci, P.6
-
36
-
-
0028125930
-
Development and small-scale production of a severely heated factor VIII concentrate
-
Knevelman A, de Wit HJ, Potstra P, vd Does JA. 1994. Development and small-scale production of a severely heated factor VIII concentrate. Vox Sanguinis 66(2):89-95.
-
(1994)
Vox Sanguinis
, vol.66
, Issue.2
, pp. 89-95
-
-
Knevelman, A.1
de Wit, H.J.2
Potstra, P.3
Vd Does, J.A.4
-
37
-
-
0029443612
-
A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland
-
Ludlam CA, Lowe GD, Mayne EE. 1995. A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland. Transfus Med 5(4):289-292.
-
(1995)
Transfus Med
, vol.5
, Issue.4
, pp. 289-292
-
-
Ludlam, C.A.1
Lowe, G.D.2
Mayne, E.E.3
-
38
-
-
8044253418
-
Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M
-
Lee C, Barrowcliffe T, Bray G, Gomperts E, Hubbard A, Kemball-Cook G, Lilley P, Owens D, Von Tilberg L, Pasi J. 1996. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 76(6):950-956.
-
(1996)
Thromb Haemost
, vol.76
, Issue.6
, pp. 950-956
-
-
Lee, C.1
Barrowcliffe, T.2
Bray, G.3
Gomperts, E.4
Hubbard, A.5
Kemball-Cook, G.6
Lilley, P.7
Owens, D.8
Von Tilberg, L.9
Pasi, J.10
-
39
-
-
0030855794
-
Second generation, B-domain deleted recombinant factor VIII
-
Berntorp E. 1997. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 78(1):256-260.
-
(1997)
Thromb Haemost
, vol.78
, Issue.1
, pp. 256-260
-
-
Berntorp, E.1
-
40
-
-
0030940593
-
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
-
Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. 1997. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 3(2):96-101.
-
(1997)
Haemophilia
, vol.3
, Issue.2
, pp. 96-101
-
-
Carlsson, M.1
Berntorp, E.2
Björkman, S.3
Lethagen, S.4
Ljung, R.5
-
41
-
-
0031059825
-
Recombinant, B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients
-
Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C. 1997. Recombinant, B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 77(2):298-302.
-
(1997)
Thromb Haemost
, vol.77
, Issue.2
, pp. 298-302
-
-
Fijnvandraat, K.1
Berntorp, E.2
ten Cate, J.W.3
Johnsson, H.4
Peters, M.5
Savidge, G.6
Tengborn, L.7
Spira, J.8
Stahl, C.9
-
42
-
-
0030972289
-
Comparative study of four different pharmacokinetic computer programs: Case study of a factor VIII preparation
-
Pascual B, Montoro JB. 1997. Comparative study of four different pharmacokinetic computer programs: Case study of a factor VIII preparation. Eur J Clin Pharmacol 52(1):59-64.
-
(1997)
Eur J Clin Pharmacol
, vol.52
, Issue.1
, pp. 59-64
-
-
Pascual, B.1
Montoro, J.B.2
-
43
-
-
0032908392
-
Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients
-
Deitcher SR, Tuller J, Johnson JA. 1999. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia 5(2):88-95.
-
(1999)
Haemophilia
, vol.5
, Issue.2
, pp. 88-95
-
-
Deitcher, S.R.1
Tuller, J.2
Johnson, J.A.3
-
44
-
-
0032751069
-
Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay
-
Lee CA, Owens D, Bray G, Giangrande P, Collins P, Hay C, Gomperts E, Schroth P, Barrowcliffe T. 1999. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 82(6):1644-1647.
-
(1999)
Thromb Haemost
, vol.82
, Issue.6
, pp. 1644-1647
-
-
Lee, C.A.1
Owens, D.2
Bray, G.3
Giangrande, P.4
Collins, P.5
Hay, C.6
Gomperts, E.7
Schroth, P.8
Barrowcliffe, T.9
-
45
-
-
0032878362
-
Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate
-
Saez A, Bosh N, Boadas N, Arguello A, Horvat D, Dinapoli G, Lisciani R. 1999. Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate. Haemophilia 5(4):260-265.
-
(1999)
Haemophilia
, vol.5
, Issue.4
, pp. 260-265
-
-
Saez, A.1
Bosh, N.2
Boadas, N.3
Arguello, A.4
Horvat, D.5
Dinapoli, G.6
Lisciani, R.7
-
46
-
-
0034045817
-
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group
-
Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. 2000. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group. Thromb Haemost 83(6):811-816.
-
(2000)
Thromb Haemost
, vol.83
, Issue.6
, pp. 811-816
-
-
Abshire, T.C.1
Brackmann, H.H.2
Scharrer, I.3
Hoots, K.4
Gazengel, C.5
Powell, J.S.6
Gorina, E.7
Kellermann, E.8
Vosburgh, E.9
-
47
-
-
0034024658
-
Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A
-
Powell JS, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson AR, Hurst D. 2000. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. Haemophilia 6(3):140-149.
-
(2000)
Haemophilia
, vol.6
, Issue.3
, pp. 140-149
-
-
Powell, J.S.1
Bush, M.2
Harrison, J.3
Abildgaard, C.4
Vosburgh, E.5
Thompson, A.R.6
Hurst, D.7
-
48
-
-
0034220228
-
Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A
-
Shirahata A, Fukutake K, Takamatsu J, Shima M, Yoshioka A. 2000. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A. Int J Hematol 72(1):101-107.
-
(2000)
Int J Hematol
, vol.72
, Issue.1
, pp. 101-107
-
-
Shirahata, A.1
Fukutake, K.2
Takamatsu, J.3
Shima, M.4
Yoshioka, A.5
-
49
-
-
0034964673
-
Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients
-
Courter SG, Bedrosian CL. 2001. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 38(2 Suppl 4 ):44-51.
-
(2001)
Semin Hematol
, vol.38
, Issue.2 SUPPL 4
, pp. 44-51
-
-
Courter, S.G.1
Bedrosian, C.L.2
-
50
-
-
0036017366
-
Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII
-
Brinkhous K, Sandberg H, Widlund L, Read M, Nichols T, Sigman J, Oswaldsson U, Schaub RG, Mikaelsson M. 2002. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost 28(3):269-272.
-
(2002)
Semin Thromb Hemost
, vol.28
, Issue.3
, pp. 269-272
-
-
Brinkhous, K.1
Sandberg, H.2
Widlund, L.3
Read, M.4
Nichols, T.5
Sigman, J.6
Oswaldsson, U.7
Schaub, R.G.8
Mikaelsson, M.9
-
51
-
-
0036257628
-
European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients
-
Rothschild C, Scharrer I, Brackmann HH, Stieltjes N, Vicariot M, Torchet MF, Effenberger W. 2002. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 8 Suppl 2:10-14.
-
(2002)
Haemophilia
, vol.8
, Issue.SUPPL 2
, pp. 10-14
-
-
Rothschild, C.1
Scharrer, I.2
Brackmann, H.H.3
Stieltjes, N.4
Vicariot, M.5
Torchet, M.F.6
Effenberger, W.7
-
52
-
-
0036565867
-
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model
-
Singh I, Smith A, Vanzieleghem B, Collen D, Burnand K, Saint-Remy JM, Jacquemin M. 2002. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 99(9):3235-3240.
-
(2002)
Blood
, vol.99
, Issue.9
, pp. 3235-3240
-
-
Singh, I.1
Smith, A.2
Vanzieleghem, B.3
Collen, D.4
Burnand, K.5
Saint-Remy, J.M.6
Jacquemin, M.7
-
53
-
-
0037764676
-
Pharmacokinetics of factor VIII and factor IX
-
discussion 100.
-
Morfini M. 2003. Pharmacokinetics of factor VIII and factor IX. Haemophilia 9 Suppl 1:94-99; discussion 100.
-
(2003)
Haemophilia
, vol.9
, Issue.SUPPL 1
, pp. 94-99
-
-
Morfini, M.1
-
54
-
-
2542605872
-
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards
-
Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM, ReFacto ASG. 2003. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 1(11):2283-2289.
-
(2003)
J Thromb Haemost
, vol.1
, Issue.11
, pp. 2283-2289
-
-
Morfini, M.1
Cinotti, S.2
Bellatreccia, A.3
Paladino, E.4
Gringeri, A.5
Mannucci, P.M.6
ReFacto, A.S.G.7
-
55
-
-
4944263724
-
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
-
Group R-PCS.
-
Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM, Group R-PCS. 2004. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 10(5):428-437.
-
(2004)
Haemophilia
, vol.10
, Issue.5
, pp. 428-437
-
-
Tarantino, M.D.1
Collins, P.W.2
Hay, C.R.3
Shapiro, A.D.4
Gruppo, R.A.5
Berntorp, E.6
Bray, G.L.7
Tonetta, S.A.8
Schroth, P.C.9
Retzios, A.D.10
Rogy, S.S.11
Sensel, M.G.12
Ewenstein, B.M.13
-
56
-
-
4844222953
-
Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A
-
Wolf DM, Rokicka-Milewska R, Lopaciuk S, Skotnicki AB, Klukowska A, Laguna P, Windyga J, Kotitschke R, Struff WG. 2004. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. Haemophilia 10(5):438-448.
-
(2004)
Haemophilia
, vol.10
, Issue.5
, pp. 438-448
-
-
Wolf, D.M.1
Rokicka-Milewska, R.2
Lopaciuk, S.3
Skotnicki, A.B.4
Klukowska, A.5
Laguna, P.6
Windyga, J.7
Kotitschke, R.8
Struff, W.G.9
-
57
-
-
16344370554
-
B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: A randomized, three-way crossover study
-
Kessler CM, Gill JC, White GC, 2nd, Shapiro A, Arkin S, Roth DA, Meng X, Lusher JM. 2005. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: A randomized, three-way crossover study. Haemophilia 11(2):84-91.
-
(2005)
Haemophilia
, vol.11
, Issue.2
, pp. 84-91
-
-
Kessler, C.M.1
Gill, J.C.2
White 2nd, G.C.3
Shapiro, A.4
Arkin, S.5
Roth, D.A.6
Meng, X.7
Lusher, J.M.8
-
58
-
-
30044450968
-
Octocog alfa, plasma/albumin-free method
-
discussion 2621-2612.
-
McCormack PL, Plosker GL. 2005. Octocog alfa, plasma/albumin-free method. Drugs 65(18):2613-2620; discussion 2621-2612.
-
(2005)
Drugs
, vol.65
, Issue.18
, pp. 2613-2620
-
-
McCormack, P.L.1
Plosker, G.L.2
-
59
-
-
33847171380
-
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A
-
Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. 2007. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit 29(1):20-26.
-
(2007)
Ther Drug Monit
, vol.29
, Issue.1
, pp. 20-26
-
-
Bolon-Larger, M.1
Chamouard, V.2
Bressolle, F.3
Boulieu, R.4
-
60
-
-
33846907893
-
ReFacto and Advate: A single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A
-
Di Paola J, Smith MP, Klamroth R, Mannucci PM, Kollmer C, Feingold J, Kessler C, Pollmann H, Morfini M, Udata C, Rothschild C, Hermans C, Janco R. 2007. ReFacto and Advate: A single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 13(2):124-130.
-
(2007)
Haemophilia
, vol.13
, Issue.2
, pp. 124-130
-
-
Di, P.J.1
Smith, M.P.2
Klamroth, R.3
Mannucci, P.M.4
Kollmer, C.5
Feingold, J.6
Kessler, C.7
Pollmann, H.8
Morfini, M.9
Udata, C.10
Rothschild, C.11
Hermans, C.12
Janco, R.13
-
61
-
-
42949112991
-
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: Results of a prospective, multicenter, open-label phase III study
-
Nemes L, Lissitchkov T, Dobaczewski G, Klukowska A, Komrska V, Zimmermann R, Auerswald G, Engl W, Abbuhl B, Pavlova BG, Ehrlich HJ. 2008. Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: Results of a prospective, multicenter, open-label phase III study. Acta Haematol 119(2):89-97.
-
(2008)
Acta Haematol
, vol.119
, Issue.2
, pp. 89-97
-
-
Nemes, L.1
Lissitchkov, T.2
Dobaczewski, G.3
Klukowska, A.4
Komrska, V.5
Zimmermann, R.6
Auerswald, G.7
Engl, W.8
Abbuhl, B.9
Pavlova, B.G.10
Ehrlich, H.J.11
-
62
-
-
38349083504
-
Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
-
Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E. 2008. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 6(2):277-283.
-
(2008)
J Thromb Haemost
, vol.6
, Issue.2
, pp. 277-283
-
-
Powell, J.S.1
Nugent, D.J.2
Harrison, J.A.3
Soni, A.4
Luk, A.5
Stass, H.6
Gorina, E.7
-
63
-
-
69949106861
-
Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes
-
Dayan I, Robinson M, Baru M. 2009. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes. Haemophilia 15(5):1006-1013.
-
(2009)
Haemophilia
, vol.15
, Issue.5
, pp. 1006-1013
-
-
Dayan, I.1
Robinson, M.2
Baru, M.3
-
64
-
-
65449189117
-
Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia
-
Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A. 2009. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia 15(3):676-685.
-
(2009)
Haemophilia
, vol.15
, Issue.3
, pp. 676-685
-
-
Martinowitz, U.1
Luboshitz, J.2
Bashari, D.3
Ravid, B.4
Gorina, E.5
Regan, L.6
Stass, H.7
Lubetsky, A.8
-
65
-
-
70350500718
-
Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice
-
Pan J, Liu T, Kim JY, Zhu D, Patel C, Cui ZH, Zhang X, Newgren JO, Reames A, Canivel D, Jesmok G, Pierce GF, Sommer JM, Jiang H. 2009. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood 114(13):2802-2811.
-
(2009)
Blood
, vol.114
, Issue.13
, pp. 2802-2811
-
-
Pan, J.1
Liu, T.2
Kim, J.Y.3
Zhu, D.4
Patel, C.5
Cui, Z.H.6
Zhang, X.7
Newgren, J.O.8
Reames, A.9
Canivel, D.10
Jesmok, G.11
Pierce, G.F.12
Sommer, J.M.13
Jiang, H.14
-
66
-
-
67649855138
-
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: Demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII
-
Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O'Brien A, Hayward B, Udata C, Roth DA, Arkin S. 2009. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: Demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 15(4):869-880.
-
(2009)
Haemophilia
, vol.15
, Issue.4
, pp. 869-880
-
-
Recht, M.1
Nemes, L.2
Matysiak, M.3
Manco-Johnson, M.4
Lusher, J.5
Smith, M.6
Mannucci, P.7
Hay, C.8
Abshire, T.9
O'Brien, A.10
Hayward, B.11
Udata, C.12
Roth, D.A.13
Arkin, S.14
-
67
-
-
65449137867
-
Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII)
-
Santoro C, Iorio A, Ferrante F, Pallotta A, Pignoloni P, Biondo F, Agnelli G, Mazzucconi MG. 2009. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 15(3):779-787.
-
(2009)
Haemophilia
, vol.15
, Issue.3
, pp. 779-787
-
-
Santoro, C.1
Iorio, A.2
Ferrante, F.3
Pallotta, A.4
Pignoloni, P.5
Biondo, F.6
Agnelli, G.7
Mazzucconi, M.G.8
-
68
-
-
65549169628
-
Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A
-
Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein BM. 2009. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther 9(3):273-283.
-
(2009)
Expert Opin Biol Ther
, vol.9
, Issue.3
, pp. 273-283
-
-
Shapiro, A.1
Gruppo, R.2
Pabinger, I.3
Collins, P.W.4
Hay, C.R.5
Schroth, P.6
Casey, K.7
Patrone, L.8
Ehrlich, H.9
Ewenstein, B.M.10
-
69
-
-
79951788029
-
Pharmacokinetics of Optivate((R)), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A
-
Dmoszynska A, Hellmann A, Baglin T, O'Shaugnessy D, Trelinski J, Kuliczkowski K, Kloczko J, Hay C, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. 2011. Pharmacokinetics of Optivate((R)), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. Haemophilia 17(2):185-190.
-
(2011)
Haemophilia
, vol.17
, Issue.2
, pp. 185-190
-
-
Dmoszynska, A.1
Hellmann, A.2
Baglin, T.3
O'Shaugnessy, D.4
Trelinski, J.5
Kuliczkowski, K.6
Kloczko, J.7
Hay, C.8
Zawilska, K.9
Makris, M.10
Shaikh-Zaidi, R.11
Gascoigne, E.12
Dash, C.13
-
70
-
-
80052023709
-
Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII
-
El-Ekiaby M, Goubran HA, Radosevich M, Abd-Allah A, El-Ekiaby A, Burnouf T. 2011. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. Haemophilia 17(5):e884-e888.
-
(2011)
Haemophilia
, vol.17
, Issue.5
-
-
El-Ekiaby, M.1
Goubran, H.A.2
Radosevich, M.3
Abd-Allah, A.4
El-Ekiaby, A.5
Burnouf, T.6
-
71
-
-
80052033319
-
Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs
-
Karpf DM, Kjalke M, Thim L, Agerso H, Merricks EP, Defriess N, Nichols TC, Ezban M. 2011. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia 17(5):e963-e968.
-
(2011)
Haemophilia
, vol.17
, Issue.5
-
-
Karpf, D.M.1
Kjalke, M.2
Thim, L.3
Agerso, H.4
Merricks, E.P.5
Defriess, N.6
Nichols, T.C.7
Ezban, M.8
-
72
-
-
84857936508
-
Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE(R))-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A
-
Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, Santagostino E, Tiede A, Viuff D. 2011. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE(R))-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 17(6):854-859.
-
(2011)
Haemophilia
, vol.17
, Issue.6
, pp. 854-859
-
-
Martinowitz, U.1
Bjerre, J.2
Brand, B.3
Klamroth, R.4
Misgav, M.5
Morfini, M.6
Santagostino, E.7
Tiede, A.8
Viuff, D.9
-
73
-
-
84355162247
-
Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice
-
Elm T, Karpf DM, Ovlisen K, Pelzer H, Ezban M, Kjalke M, Tranholm M. 2012. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia 18(1):139-145.
-
(2012)
Haemophilia
, vol.18
, Issue.1
, pp. 139-145
-
-
Elm, T.1
Karpf, D.M.2
Ovlisen, K.3
Pelzer, H.4
Ezban, M.5
Kjalke, M.6
Tranholm, M.7
-
74
-
-
84863193826
-
Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice
-
Shi Q, Kuether EL, Schroeder JA, Fahs SA, Montgomery RR. 2012. Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice. Haemophilia 18(4):639-646.
-
(2012)
Haemophilia
, vol.18
, Issue.4
, pp. 639-646
-
-
Shi, Q.1
Kuether, E.L.2
Schroeder, J.A.3
Fahs, S.A.4
Montgomery, R.R.5
-
75
-
-
84879029262
-
-
Baxter Healthcare Corporation. Dose-response study of recomb ant factor VIII manufactured prote -free (rAHF-PFM) patients with hemophilia A. Clinicaltrialsgov. Bethesda, Maryland: National Library of Medicine (US) [cited December 7, 2012].
-
Baxter Healthcare Corporation. 2000. Dose-response study of recombinant factor VIII manufactured protein-free (rAHF-PFM) in patients with hemophilia A. Clinicaltrialsgov. Bethesda, Maryland: National Library of Medicine (US) [cited December 7, 2012].
-
(2000)
-
-
-
76
-
-
84879014780
-
-
Baxter Healthcare Corporation. Pharmacok etic study of ADVATE reconstituted 2 mL sterile water for jection. Clinicaltrialsgov. Bethesda, Maryland: National Library of Medicine (US) [cited December 7, 2012].
-
Baxter Healthcare Corporation. 2000. Pharmacokinetic study of ADVATE reconstituted in 2 mL sterile water for injection. Clinicaltrialsgov. Bethesda, Maryland: National Library of Medicine (US) [cited December 7, 2012].
-
(2000)
-
-
-
77
-
-
2542628723
-
The factor VIII assay problem: Neither rhyme nor reason
-
Lollar P. 2003. The factor VIII assay problem: Neither rhyme nor reason. J Thromb Haemost 1(11):2275-2279.
-
(2003)
J Thromb Haemost
, vol.1
, Issue.11
, pp. 2275-2279
-
-
Lollar, P.1
-
78
-
-
0023033053
-
Man versus beast: Pharmacokinetic scaling in mammals
-
Mordenti J. 1986. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75(11):1028-1040.
-
(1986)
J Pharm Sci
, vol.75
, Issue.11
, pp. 1028-1040
-
-
Mordenti, J.1
-
79
-
-
0018198995
-
Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII
-
Over J, Sixma JJ, Bruine MH, Trieschnigg MC, Vlooswijk RA, Beeser-Visser NH, Bouma BN. 1978. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J Clin Invest 62(2):223-234.
-
(1978)
J Clin Invest
, vol.62
, Issue.2
, pp. 223-234
-
-
Over, J.1
Sixma, J.J.2
Bruine, M.H.3
Trieschnigg, M.C.4
Vlooswijk, R.A.5
Beeser-Visser, N.H.6
Bouma, B.N.7
-
80
-
-
79951472629
-
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
-
Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. 2011. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17(1):2-10.
-
(2011)
Haemophilia
, vol.17
, Issue.1
, pp. 2-10
-
-
Collins, P.W.1
Fischer, K.2
Morfini, M.3
Blanchette, V.S.4
Bjorkman, S.5
-
82
-
-
74749088747
-
Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A
-
Porada CD, Sanada C, Long CR, Wood JA, Desai J, Frederick N, Millsap L, Bormann C, Menges SL, Hanna C, Flores-Foxworth G, Shin T, Westhusin ME, Liu W, Glimp H, Zanjani ED, Lozier JN, Pliska V, Stranzinger G, Joerg H, Kraemer DC, Almeida-Porada G. 2010. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost 8(2):276-285.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.2
, pp. 276-285
-
-
Porada, C.D.1
Sanada, C.2
Long, C.R.3
Wood, J.A.4
Desai, J.5
Frederick, N.6
Millsap, L.7
Bormann, C.8
Menges, S.L.9
Hanna, C.10
Flores-Foxworth, G.11
Shin, T.12
Westhusin, M.E.13
Liu, W.14
Glimp, H.15
Zanjani, E.D.16
Lozier, J.N.17
Pliska, V.18
Stranzinger, G.19
Joerg, H.20
Kraemer, D.C.21
Almeida-Porada, G.22
more..
-
83
-
-
78149246105
-
WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A
-
Booth CJ, Brooks MB, Rockwell S, Murphy JW, Rinder HM, Zelterman D, Paidas MJ, Compton SR, Marks PW. 2010. WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. J Thromb Haemost 8(11):2472-2477.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.11
, pp. 2472-2477
-
-
Booth, C.J.1
Brooks, M.B.2
Rockwell, S.3
Murphy, J.W.4
Rinder, H.M.5
Zelterman, D.6
Paidas, M.J.7
Compton, S.R.8
Marks, P.W.9
-
84
-
-
0003720769
-
-
Cambridge [Eng.]University press. Cambridge, England. xv
-
Thompson DAW. 1917. On growth and form. Cambridge [Eng.]University press. Cambridge, England. xv, 793 p.
-
(1917)
On growth and form
, pp. 793
-
-
Thompson, D.A.W.1
-
85
-
-
33344457255
-
A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry
-
Tang H, Mayersohn M. 2006. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95(8):1783-1799.
-
(2006)
J Pharm Sci
, vol.95
, Issue.8
, pp. 1783-1799
-
-
Tang, H.1
Mayersohn, M.2
-
86
-
-
80052173934
-
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a
-
Hu X, Olivier K, Polack E, Crossman M, Zokowski K, Gronke RS, Parker S, Li Z, Nestorov I, Baker DP, Clarke J, Subramanyam M. 2011. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J Pharmacol Exp Ther 338(3):984-996.
-
(2011)
J Pharmacol Exp Ther
, vol.338
, Issue.3
, pp. 984-996
-
-
Hu, X.1
Olivier, K.2
Polack, E.3
Crossman, M.4
Zokowski, K.5
Gronke, R.S.6
Parker, S.7
Li, Z.8
Nestorov, I.9
Baker, D.P.10
Clarke, J.11
Subramanyam, M.12
-
87
-
-
78651400009
-
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned
-
Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. 2011. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? mAbs 3(1):61-66.
-
(2011)
mAbs
, vol.3
, Issue.1
, pp. 61-66
-
-
Deng, R.1
Iyer, S.2
Theil, F.P.3
Mortensen, D.L.4
Fielder, P.J.5
Prabhu, S.6
-
88
-
-
0037384789
-
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin
-
Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. 2003. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31(4):290-299.
-
(2003)
Exp Hematol
, vol.31
, Issue.4
, pp. 290-299
-
-
Egrie, J.C.1
Dwyer, E.2
Browne, J.K.3
Hitz, A.4
Lykos, M.A.5
-
89
-
-
0036881075
-
Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis
-
Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, Heatherington AC, Maroni BJ. 2002. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 72(5):546-555.
-
(2002)
Clin Pharmacol Ther
, vol.72
, Issue.5
, pp. 546-555
-
-
Allon, M.1
Kleinman, K.2
Walczyk, M.3
Kaupke, C.4
Messer-Mann, L.5
Olson, K.6
Heatherington, A.C.7
Maroni, B.J.8
|